Short-Term Debt to Capital: niagenbioscience.com (NAGE)

Chromadex Corp (NAGE) holds exclusive rights to a cellular regeneration component, benefiting from global licensing royalties. The business model relies on outsourced Niagen synthesis and direct online sales, converting promotion into high margins. Historical price action at the value of 0.01 confirms the status of a player that, thanks to unique bio-assets, dictates premium terms to the market, eliminating the risk of cheap analogues emerging.

This indicator measures the proportion of short-term liabilities within the equity structure, determining the balance between operational flexibility and liquidity risk. Analyzing short-term loans relative to equity allows for an assessment of how effectively Chromadex Corp (NAGE) finances its scientific partnerships and dietary supplement ingredient supplies without incurring a critical debt load that could limit the development of healthy aging technologies.